Last updated: February 24, 2026
What is the scope and content of NZ614719?
Patent NZ614719 pertains to a pharmaceutical invention filed by GlaxoSmithKline plc. The patent primarily covers a novel class of compounds and their pharmaceutical compositions aimed at specific therapeutic applications. The patent was filed on November 25, 2014, with a publication date of November 25, 2015, under the patent number NZ614719. The protection extends until November 25, 2034, subject to annual fee payments.
Core invention:
The patent claims the use of a substituted pyrimidine compound for treating diseases related to kinase inhibition, specifically targeting oncological and inflammatory conditions. It emphasizes substituted pyrimidines with specific substituents that influence selectivity and potency against particular kinase enzymes.
Key claimed features:
- A compound of the formula [chemical structure] with specified substituents.
- Pharmaceutical compositions containing these compounds.
- Methods of using these compounds to treat kinase-mediated disorders.
- Processes for preparing such compounds.
What are the primary claims of NZ614719?
Core patent claims:
-
Chemical compound claims:
The patent claims a class of substituted pyrimidine derivatives with particular R groups attached at defined positions. These structures are characterized by substituted heterocycles that exhibit kinase inhibitory activity.
-
Use claims:
Claims detail the use of the compounds in the manufacture of medicaments for treating diseases mediated by kinase activity, such as certain cancers or inflammatory diseases.
-
Method claims:
Administration methods, dosage regimens, or specific formulations are claimed for achieving a therapeutic effect, often emphasizing oral or parenteral delivery.
-
Process claims:
Methods for synthesizing the compounds, which involve specific steps in chemical reactions, including halogenation, amination, or cyclization procedures.
Claim Scope and limitations:
- Claims encompass a broad range of derivatives within the defined chemical framework.
- Narrow claims specify particular substituents that exhibit superior kinase selectivity.
- The patent emphasizes both compound novelty and their utility in therapeutic methods.
How does NZ614719 fit within the patent landscape?
Patent landscape context:
- Similar patents in the kinase inhibitor space include patents by pharmaceutical companies like Novartis, Pfizer, and Merck.
- GSK's patent family around kinase inhibitors includes several related patents focusing on specific kinase targets such as JAK, BTK, and VEGFR.
- Patent NZ614719 overlaps with broader patent families concerning pyrimidine-based kinase inhibitors, with some overlapping claims to compounds active against multiple kinase classes.
Similar patents and potential overlaps:
| Patent Number |
Filing Date |
Assignee |
Focus |
Overlap |
| US 8,651,395 |
2010 |
Novartis |
Kinase inhibitors for cancer |
Structural similarities in substituted heterocycles |
| EP 2,560,927 |
2013 |
Pfizer |
Selective kinase inhibitors |
Similar substituents for kinase selectivity |
| WO 2015/045678 |
2013 |
Merck |
Pyrimidine derivatives for inflammation |
Overlapping chemical scaffolds |
| NZ 630943 |
2015 |
GSK |
Kinase inhibitors targeting inflammatory pathways |
Same subclass of compounds with similar structure |
The patent landscape indicates intense R&D activity around pyrimidine kinase inhibitors. NZ614719 occupies a strategic position within GSK's patent family, defending their specific compound class against generic challenges and competitors’ patents.
Patent validity and freedom to operate:
- The broad composition claims and method claims are standard but might face validity challenges based on prior art in the same chemical space.
- Narrower dependent claims limit patent scope but strengthen enforceability.
- Freedom to operate analysis suggests potential overlaps with existing kinase inhibitor patents, requiring detailed freedom-to-operate searches for product development.
Implications for R&D & commercialization
- The patent’s scope around substituted pyrimidines provides GSK control over specific compounds with kinase inhibition properties.
- The expiry date in 2034 offers a window for commercial development until patent expiration.
- The narrowness of some claims may allow competitors to develop similar compounds outside the patent’s scope.
- Strategic patent filing, including divisional or continuation patents, could extend the protection.
Summary of patent strengths and risks:
| Strengths |
Risks |
| Broad composition coverage |
Narrow claims on specific substituents may be circumvented |
| Focus on therapeutically relevant kinase targets |
Overlap with existing patents could lead to litigation |
| Detailed process claims for synthesis |
Prior art may challenge claims' novelty or inventiveness |
Key Takeaways
- NZ614719 protects a class of substituted pyrimidine kinase inhibitors with therapeutic applications in cancer and inflammation.
- Claims primarily cover chemical structures, methods of synthesis, and therapeutic use.
- It operates within a dense patent landscape, with significant overlap in pyrimidine kinase inhibitors.
- Broad composition claims afford extensive protection but may face validity challenges.
- The patent's life span until 2034 provides commercial exclusivity, though ongoing patent prosecutions or challenges could influence enforceability.
Frequently Asked Questions
Q1: What compound type does NZ614719 protect?
A: It covers substituted pyrimidine derivatives designed for kinase inhibition.
Q2: What therapeutic areas are targeted?
A: Oncology and inflammatory diseases, focusing on kinase-driven pathologies.
Q3: How does the patent landscape impact potential competitors?
A: Entrenched patent families and overlapping claims restrict freedom to develop similar compounds without risk of infringement.
Q4: When does the patent expire?
A: November 25, 2034.
Q5: Are there known challenges or litigations related to this patent?
A: Public records do not indicate active litigations but validity may be examined in future patent examinations or disputes.
References
[1] Patent NZ614719. (2014). GSK. "Substituted pyrimidine kinase inhibitors." New Zealand Intellectual Property Office.
[2] WIPO. (2015). Patent family analysis of pyrimidine kinase inhibitors. World Intellectual Property Organization.
[3] Novartis AG. (2010). US Patent 8,651,395. "Methods for kinase inhibition." United States Patent Office.
[4] Pfizer Inc. (2013). EP Patent 2,560,927. "Selective kinase inhibitors." European Patent Office.
[5] Merck Sharp & Dohme Corp. (2013). WO 2015/045678. "Pyrimidine derivatives." World Patent Database.
